Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT05274347

A Virtual Post-Discharge Intervention For Patients With CKD

This pilot, interventional study is testing a combination of remote, virtual interventions, delivered to patients at home to patients with chronic kidney disease (CKD), with the goal of reducing admissions to hospital.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

About this study

Chronic kidney disease and kidney failure increase the risk of hospitalizations. Many hospital admissions are potentially avoidable. This pilot, interventional study is testing a combination of remote, virtual interventions, delivered to patients at home, with the goal of reducing admissions to hospital. The hypothesis for this pilot work is that the proposed interventions will be adopted by patients and will improve mental health, physical function, quality of life, and disease self-management, which are all key potential mediators of hospital readmission risk in patients with chronic kidney disease.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults with CKD (defined as an estimated glomerular filtration rate <30mL/min/1.73m2, including hemodialysis)
  • Able to provide informed consent.
  • Ongoing follow-up by the St Joseph's Hospital Hamilton Kidney Care Clinic or Dialysis Program and with a recent hospital admission.

Exclusion criteria

  • Unable to speak or understand English.
  • Significant cognitive impairment (as per the treating inpatient care team)
  • Serious mental illness (schizophrenia, severe untreated bipolar disorder, psychosis, active suicidal ideation)
  • Significant vision or hearing impairment that prevents use of the technology or participation in any of the intervention components.
  • Being discharged to long-term care, rehab or complex care.
  • Peritoneal dialysis
  • Home hemodialysis
  • Functioning kidney transplant

Treatment and study plan

Muti-faceted virtual, remote intervention

Other

Patients will be provided with tablets with internet connectivity and Aetonix software, along with a blood pressure cuff, weigh scale and pulse oximeter with blue tooth capability. These will be used to deliver virtual CBT sessions as well as remote monitoring of vital signs, symptoms and enhanced communication. The intervention duration will be 10 weeks.

Primary outcomes

  1. Patient uptake of the intervention

    Time frame: 10 weeks

    Patient use of the Aetonix platform and virtual intervention components. Uptake of the virtual CBT intervention will be determined by the number of attended sessions.

  2. Patient acceptance of the intervention

    Time frame: 10 weeks

    Acceptability of the technology will be determined by the proportion of patients who provide a mean Telehealth Usability Questionnaire (TUQ) score >5/7. The mean TUQ score ranges from 1 to 7, with a higher score indicating greater acceptance of the intervention.

Secondary outcomes

  1. Patients' reasons for not participating in virtual sessions.

    Time frame: 10 weeks

    This will be collected for further detail on the uptake of the intervention.

  2. Patient satisfaction with the intervention

    Time frame: Measured at 10 weeks (study end)

    Satisfaction with both the technology and virtual physiotherapy and CBT sessions. This outcome will be determined using a locally developed patient experience survey instrument that includes 13 questions asking patients to rate various elements of the intervention with the response options "strongly disagree", "disagree", "neutral", "agree", "strongly agree". The Satisfaction with Therapy and Therapist Scale- Revised (STTS-R) will be used to measure satisfaction with the CBT intervention.

  3. Uptake of systolic and diastolic blood pressure monitoring

    Time frame: 10 weeks

    Mean number of missing blood pressure values per patient.

  4. Changes in management as a result of remote monitoring

    Time frame: 10 weeks

    Mean number of alert values per patient from the monitoring pathway, mean number of alerts that resulted in a change in management per patient, mean number of medication errors detected per patient

  5. Change in depression

    Time frame: 10 weeks

    Change in Patient Health Questionnaire-9 (PHQ-9) score (measured every 2 weeks). The PHQ-9 score ranges from 0 to 27. A higher score indicates a higher degree of depressive symptoms.

  6. Change in anxiety

    Time frame: 10 weeks

    Change in Generalized Anxiety Disorder-7 (GAD-7) score (measured every 2 weeks). The GAD-7 score ranges from 0 to 21, with a higher score indicating a higher degree of anxiety.

  7. Change in disease self-efficacy

    Time frame: 10 weeks

    Change in Self Efficacy for Managing Chronic Disease (SEMCD) score (measured every 2 weeks). The SEMCD score is the mean score from 6 items, with a means score range from 1 to 10. A higher score indicates higher self-efficacy

  8. Change in overall self-reported health

    Time frame: 10 weeks

    Measured every 2 weeks using the single question Global QOL score. Participants will be asked to rate their overall health as "excellent, good, fair, or poor".

  9. Change in self-reported quality of life

    Time frame: 10 weeks

    measured week 1, week 5 and week 10 using the Short Form-36 (SF-36) questionnaire. Scores range from 0 - 100 Lower scores = more disability, higher scores = less disability

  10. Questionnaire completion

    Time frame: 10 weeks

    Mean number of incomplete questionnaires per patient

  11. All-cause hospitalizations

    Time frame: 10 weeks

    Hospitalizations will be determined by patient report directly into their Aetonix tablet (weekly question) or clinical staff following up on alerts for missed CBT/physio sessions or >3 consecutive missed daily symptom/vitals questionnaires.

  12. Emergency room visits

    Time frame: 10 weeks

    Emergency room visits will be determined by patient report directly into their Aetonix tablet (weekly question) or clinical staff following up on alerts for missed CBT/physio sessions or >3 consecutive missed daily symptom/vitals questionnaires.

Study contacts

Contact information is provided by the study sponsor or research team.

Amber O Molnar, MD, MSc

CONTACT

[email protected]

905-522-1156 ext. 33191

Sponsors and collaborators

Lead sponsor

McMaster University

Other

Registry information

Official study title

A Virtual Post-Discharge Intervention to Prevent Hospital Re-Admissions in Patients With CKD

Acronym: VIDIO-CKD

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Mar 10, 2022
Registry last updated
Dec 16, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.